Guideline development group was not in the pocket of pharma

Welfare makes valid observations about the lack of good quality evidence for prophylaxis against venous thromboembolism in general medical patients and criticises the use of surrogate end points—in principle, he is right.1 If ample randomised evidence with the end points of fatal bleeds versus fatal embolism had existed we would have used that alone. The National Institute for Health and Clinical Excellence (NICE) guideline group found that, …